The Rel/NF-kappa B family transcriptional factors plays an important role in the regulation of immune and acute phase responses. The activity of Rel/NF-kappa B complexes is regulated by their interactions with members of the I kappa B family of inhibitors. We have previously shown that the RelB/p52 heterodimer is not effectively inhibited by any of the known I kappa B molecules: I kappa B alpha, I kappa B gamma and Bcl3. Here we report that the C-terminal domain of p100 (the putative I kappa B delta) functions as a strong inhibitor of RelB/p52 transcriptional activity. In vivo interaction with I kappa B delta leads to the cytoplasmic retention and decreased DNA binding activity of RelB/p52 complexes. Thus, I kappa B delta is the only I kappa B molecule able to efficiently modulate the activity of RelB/p52 heterodimer. In Daudi cells, a 46 kD protein, probably representing the C-terminal product of the proteolytic processing of p100, remains associated with Rel/NF-kappa B complexes and might have a transient regulatory function. Our results indicate a specific role for the putative I kappa B delta and suggest a possible mechanism of how the truncation of the ankyrin domain of p100, found in a number of lymphoid neoplasias, might contribute to tumorigenesis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

kappa delta
16
domain p100
12
kappa
9
relb/p52 transcriptional
8
transcriptional activity
8
c-terminal domain
8
rel/nf-kappa complexes
8
relb/p52 heterodimer
8
putative kappa
8
activity relb/p52
8

Similar Publications

Buprenorphine is an agonist at the mu opioid receptor (MOR) and antagonist at the kappa (KOR) and delta (DOR) receptors and a nociceptin receptor (NOR) ligand. Buprenorphine has a relatively low intrinsic efficacy for G-proteins and a long brain and MOR dwell time. Buprenorphine ceiling on respiratory depression has theoretically been related multiple factors such as low intrinsic efficacy at MOR, binding to six-transmembrane MOR and interactions in MOR/NOR heterodimers.

View Article and Find Full Text PDF

Novel tertiary diarylethylamines as functionally selective agonists of the kappa opioid receptor.

Bioorg Med Chem Lett

January 2025

Contineum Therapeutics, 3565 General Atomics Court, Suite 200, San Diego, CA 92121, United States.

Novel kappa opioid receptor (KOR) agonists that preferentially activate G-protein signaling versus β-arrestin-2 recruitment are described. Starting from a literature-reported phenol-containing diphenethylamine KOR agonist, structure-activity relationship (SAR) studies revealed replacement of the phenol with various non-hydroxylated bicyclic heteroaromatics led to tertiary diarylethylamines which retained KOR agonist activity and improved metabolic stability in human liver microsomes. Further optimizations produced compound 39, a potent activator of G-protein signaling (GTPγS EC = 14 nM, 83 % E) that did not elicit a β-arrestin-2 recruitment functional response (E < 10 %).

View Article and Find Full Text PDF

Salt marsh vegetation in the Yellow River Delta, including (), (), and (), is essential for the stability of wetland ecosystems. In recent years, salt marsh vegetation has experienced severe degradation, which is primarily due to invasive species and human activities. Therefore, the accurate monitoring of the spatial distribution of these vegetation types is critical for the ecological protection and restoration of the Yellow River Delta.

View Article and Find Full Text PDF

Structure and properties of polysaccharides from tetrasporophytes of Mazzaella parksii.

Int J Biol Macromol

January 2025

G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of the Russian Academy of Sciences, 100 Let Vladivostoku Prosp., 159, 690022 Vladivostok, Russian Federation.

The structure and anti-SARS-CoV-2 activity of sulfated polysaccharides (Mzpt) obtained in high yield (60 %) from tetrasporophytes of Mazzaella parksii were studied. Stepwise fractionation with KCl showed that Mzpt consisted of eight (MzptF1-MzptF8) carrageenans fractions, differing in structure and molecular weight. The yield of non-gelling MzptF8 was 58.

View Article and Find Full Text PDF

Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease.

World J Gastroenterol

January 2025

Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan.

This article discusses the recent study written by Koizumi . Alcohol-associated liver disease (ALD) is a major cause of liver-related morbidity and mortality, which is driven by complex mechanisms, including lipid accumulation, apoptosis, and inflammatory responses exacerbated by gut barrier dysfunction. The study explored the therapeutic potential of elafibranor, a dual peroxisome proliferator-activated receptor alpha/delta agonist.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!